Psoriasis Biosimilars Market Key Players Analysis 2026 to 2035
Segmentation of Psoriasis Biosimilars Market :
Psoriasis Biosimilars Market By Drug Class-
- TNF-alpha inhibitors
- Other biosimilars
Psoriasis Biosimilars Market By Route of Administration-
- Subcutaneous
- Intravenous
Psoriasis Biosimilars Market By Indication-
- Plaque psoriasis
- Psoriatic arthritis
- Other types
Psoriasis Biosimilars Market By Distribution Channel-
- Hospital pharmacies
- Retail pharmacy chains
- Online pharmacies
Psoriasis Biosimilars Market By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Afric
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psoriasis Biosimilars Market Snapshot
Chapter 4. Global Psoriasis Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Psoriasis Biosimilars Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Psoriasis Biosimilars Industry Trends
Chapter 5. Psoriasis Biosimilars Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. Market Share by Drug Class, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:
5.2.1. TNF-alpha Inhibitors
5.2.1.1. Infliximab
5.2.1.2. Etanercept
5.2.1.3. Adalimumab
5.2.2. Other Biosimilars
Chapter 6. Psoriasis Biosimilars Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indications:
6.2.1. Plaque Psoriasis
6.2.2. Psoriatic Arthritis
6.2.3. Other Types
Chapter 7. Psoriasis Biosimilars Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administrations:
7.2.1. Subcutaneous
7.2.2. Intravenous
Chapter 8. Psoriasis Biosimilars Market Segmentation 4: By Sales Channel, Estimates & Trend Analysis
8.1. Market Share by Sales Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Sales Channels:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacy Chains
8.2.3. Online Pharmacies
Chapter 9. Psoriasis Biosimilars Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Psoriasis Biosimilars Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.2.3. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.2.4. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.2.5. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.3. Europe
9.3.1. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.3.3. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.3.4. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.3.5. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.4.3. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.4.4. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.4.5. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.5. Latin America
9.5.1. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.5.3. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.5.4. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.5.5. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.6.3. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.6.4. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.6.5. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Alvotech
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial PerDrug Classance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Amgen Inc.
10.2.3. Biocon
10.2.4. Biogen
10.2.5. Biosimilar Collaborations Ireland Limited
10.2.6. Boeheringer Ingelheim
10.2.7. Celltrion
10.2.8. Cipla
10.2.9. Coherus Biosciences
10.2.10. Cordavis Ltd.
10.2.11. Epirus Biopharmaceuticals
10.2.12. Fresenius Kabi
10.2.13. Glenmark Pharmaceuticals
10.2.14. Hanwha Chemical
10.2.15. Hetero
10.2.16. Innovent Biologics
10.2.17. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
10.2.18. LG Chem
10.2.19. Lupin
10.2.20. Mabpharm
10.2.21. Merck
10.2.22. Mylan
10.2.23. Nichi-Iko Pharmaceutical
10.2.24. Organon & Co.
10.2.25. Pfizer
10.2.26. Ranbaxy Laboratories (now Sun Pharma)
10.2.27. Samsung Bioepis
10.2.28. Sandoz
10.2.29. Shanghai CP Guojian Pharmaceutical
10.2.30. Sorrento Therapeutics (partner)
10.2.31. Stada Arzneimittel AG
10.2.32. Sunshine Guojian Pharmaceutical
10.2.33. Synermore
10.2.34. Teva
10.2.35. Torrent Pharmaceuticals
10.2.36. YL Biologics
10.2.37. Zydus Cadila
10.2.38. Other prominent players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Psoriasis Biosimilars Market Size is valued at USD 8.5 billion in 2023 and is predicted to reach USD 19.3 billion by the year 2031
The Psoriasis Biosimilars Market is expected to grow at a 10.9% CAGR during the forecast period for 2024-2031.
Alvotech, Amgen, Amgen Inc., Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, C
Drug Class, Route Of Administration, Indication, And Distribution Channel are the key segments of the Psoriasis Biosimilars Market.
North American region is leading the Psoriasis Biosimilars Market.